hemagglutinin [influenza a virus]

Partial antigenic glycoprotein

Influenza hemagglutinin is a type of hemagglutinin found on the surface of the influenza viruses. It is an antigenic glycoprotein. It is responsible for binding the virus to the cell that is being infected. Influenza hemagglutinin proteins bind to cells w

CEF8, Influenza Virus NP (383-391) is an influenza A virus nucleoprotein containing residues 383 to 391, is the most important HLA-B*2705-restricted epitope in the nucleoprotein of influenza A viruses and is associated with escape from cytotoxic T lymphocytes-mediated immunity.HLA-B*3501 restricted influenza virus nucleoprotein epitope (383-391).

Influenza virus-IN-5 (Compound 5f) is an influenza virus hemagglutinin (HA) inhibitor that acts on the A/H3N2 virus (EC50: 1 nM).

Influenza A virus-IN-8 (S5), a macrocyclic peptide, exhibits no cytotoxicity and functions as a potent inhibitor of Influenza A Virus (IAV), demonstrating significant protease stability. It has IC50 values of 6.7 nM for H1 and 6.6 nM for H5 variants, indicating strong inhibitory effects. Furthermore, it has a high affinity for H1 variants, binding to a conserved region in the HA stem with a dissociation constant (Kd) of 1.0 nM [1].

Influenza virus-IN-7 (Example 16) is an orally active inhibitor of cap-dependent endonuclease, employed in research on influenza viral infectious diseases [1].

Influenza virus-IN-3 (compound 9) is a potent inhibitor of selective influenza viruses, acting on H5N1 (IC50: 0.88 μM), H5N2 (IC50: 0.10 μM), H5N6 (IC50: 5.5 μM), H5N8 (IC50: 0.51 μM). Influenza virus-IN-3 has antiviral and NA (neuraminidase) inhibitory effects and low cytotoxicity (CC50>200 μM).

Influenza A virus-IN-5 (Compound 16e) is a highly potent and orally active agent against the influenza A virus (IAV), exhibiting an IC 50 of 1.29 μM. It effectively inhibits the transcription and replication of viral RNA while maintaining acceptable levels of cytotoxicity [1].

Influenza A virus-IN-7 (compound 16r) is a potent, orally active inhibitor of influenza A virus (IC50: 3.43 μM, CC50>100 μM). Influenza A virus-IN-7 is an anti-IAV agent with low cytotoxicity and inhibits viral RNA transcription and replication.

Influenza virus-IN-2 (compound 19) has anti-influenza A virus activities that is a potent inhibitor of influenza virus with an CC 50 of 150.85 μM and EC 50 of 2.58 μM. Influenza virus-IN-2 concentration-dependently inhibits the PAN endonuclease with EC 50 of 489.39 nM [1].

Influenza A virus fragment has the RNA sequence of Leu-Lys-Phe-Ala-Phe-Ser-Met-Met.

Influenza A virus-IN-4 (compound 23b), a derivative of Oseltamivir, is a highly effective neuraminidase inhibitor. It exerts potent inhibitory effects on influenza viruses [1].

Influenza A virus-IN-6 (compound 16j) is a potent and selective inhibitor of influenza A virus （IC 50= 3.88 μM, CC50= 36.64 μM). Influenza A virus-IN-6 exhibits anti-IAV activity with low cytotoxicity.

Influenza virus-IN-6 (Compound 35) serves as a potent inhibitor targeting the N-terminal domain of the polymerase acidic protein (PA N ) endonuclease subunit of the influenza virus, exhibiting an inhibitory concentration 50 (IC 50 ) value of 0.20 μM [1].

HLA-B*08 restricted influenza virus nucleoprotein epitope.

Influenza virus-IN-4 (compound 11e) is a potent inhibitor of influenza virus neuraminidase, acting on H5N1 (IC50: 3.4 μM), H5N2 (IC50: 0.094 μM), H5N6 (IC50: 0.79 μM) and H5N8 (IC50: 0.077 μM). Influenza virus-IN-4 inhibits NA (neuraminidase) and has low cytotoxicity (CC50 > 200 μM). influenza virus-IN-4 is not significantly toxic to mice at 1500 mg/kg.

Influenza A virus-IN-1, a dihydropyrrolidones derivative, is a highly effective inhibitor of various subtypes of influenza A virus (IAV) with IC 50 values ranging from 3.11 μM to 7.13 μM. It effectively suppresses IAV replication and enhances the expression of key antiviral cytokines, such as IFN-β, and the antiviral protein MxA.

Influenza virus-IN-1 (compound 14) exhibits anti-influenza A virus activities which is a potent inhibitor of influenza A virus with an CC 50 of >200 μM and EC 50 of 2.46 μM. Influenza virus-IN-1 exhibits a concentration dependent inhibition activity for PAN endonuclease (EC 50 = 312.36 nM) [1].

BMY-27709 is an influenza virus growth inhibitor with an IC50 value of 3-8 μM against A/WSN/33 virus growth, and also exhibits inhibitory activity against some subtypes of influenza viruses.BMY-27709 acts early in the course of H1 and H2 virus infections, and exhibits antiviral activity through inhibition of hemagglutinin proteins. However, BMY-27709 has no effect on H3 subtype viruses and influenza B/Lee/40 viruses.

Influenza HA 126-138 acetate is a influenza virus hemagglutinin (HA) peptide acetate comprising amino acids 126-138. Influenza HA 126-138 acetate induces thymic and peripheral T-cell apoptosis.

Influenza HA (126-138) is a peptide derived from the hemagglutinin (HA) protein of the influenza virus. It consists of amino acids 126-138 and has the ability to induce apoptosis in both thymic and peripheral T-cells.

MBX2329 is a specific inhibitor of HA-mediated viral entry that inhibits H1N1 virus strain high pathogenic avian influenza H5N1 virus strain.

Influenza HA (110-119) refers to a specific fragment (110-119) derived from the hemagglutinin protein of the influenza virus. This fragment has the ability to induce the proliferation of Treg cells.

Firivumab (CT-P22; CT120), a human IgG1 monoclonal antibody targeting influenza A virus hemagglutinin (Anti-IAV HA), demonstrates neutralization capabilities against multiple strains including H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2, and H12N7. It has also shown to protect mice from the H1N1 virus [1] [2] [3].

Ingavirin, a novel inhibitor of the influenza virus reproduction, inhubits the formation of the virus specific hemagglutinin.

Urumin, a compound with antiviral properties, inhibits human influenza A virus growth, particularly the PR8 strain, with an inhibitory concentration (IC 50) of 3.8 μM. It acts by targeting the conserved stalk of H1 hemagglutinin and can neutralize drug-resistant H1 influenza viruses. Additionally, Urumin offers protective effects against lethal influenza infection in naive mice [1].

HA-IN-1 (compound 5g), a high-affinity Hemagglutinin (HA) ligand, targets the trypsin cleavage site of HA to inhibit HA-mediated membrane fusion and decrease pulmonary virus titer in vivo. This compound emerges as a promising influenza A virus (IAV) inhibitor and anti-influenza agent [1].

JNJ4796 is an oral active fusion inhibitor of the influenza virus, by inhibiting hemagglutinin (HA)-mediated fusion to neutralizing the influenza A group 1 virus. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs).

CBS1117 is a virus entry inhibitor (IC50 of 70 nM for influenza A virus, A/Puerto Rico/8/34 (H1N1)）. It interferes with the hemagglutinin (HA)-mediated fusion process.

CAY10766 is an antiviral compound.1It inhibits entry of influenza virus-like particles pseudotyped with hemagglutinin A (HA) from H5N1 influenza A virus into A549 cells (EC50= 0.24 μM). CAY10766 (1 μM) reduces H1N1 and H5N1 influenza A viral titers in infected MDCK cells. It also exhibits synergy with oseltamivir carboxylate in MDCK cells infected with the influenza A reporter PR8-NS1-Gluc virus.

CBS1194 is a novel antiviral agent against influenza A virus (IAV), and is more specifically, a group 2 IAV fusion inhibitor. CBS1194 prevents membrane fusion of the virus through the inhibition of the conformational change of hemagglutinin (HA). CBS1194 causes steric hinderance that prevents the rearrangement of the HA that would normally be induced by low-pH, by fitting into the pocket by the fusion peptide.

PROTAC Hemagglutinin Degrader-1 (Compound V3) is a potent degrader of influenza hemaglutinin (HA), demonstrating a median degradation concentration of 1.44 μM and exhibiting broad-spectrum anti-influenza virus activity [1].

Gedivumab (MHAA4549A; RG7745), a human monoclonal antibody, exhibits high specificity in targeting the influenza A virus (IAV) by binding to the highly conserved stem region of the IAV hemagglutinin protein. This interaction inhibits hemagglutinin maturation and blocks hemagglutinin-mediated membrane fusion within the intranucleosome, making Gedivumab useful for studies on IAV infection disease [1].

Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin HA of the influenza A virus, effectively neutralizing strains H1, H2, H5, and H9 by binding to the HA2 stem fusion domain [1].